Epilepsy in a mouse model of GNB1 encephalopathy arises from altered potassium (GIRK) channel signaling and is alleviated by a GIRK inhibitor

mutations in , encoding the G subunit of G proteins, cause a neurodevelopmental disorder with global developmental delay and epilepsy, encephalopathy. Here, we show that mice carrying a pathogenic mutation, K78R, recapitulate aspects of the disorder, including developmental delay and generalized sei...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cellular neuroscience Vol. 17; p. 1175895
Main Authors Colombo, Sophie, Reddy, Haritha P, Petri, Sabrina, Williams, Damian J, Shalomov, Boris, Dhindsa, Ryan S, Gelfman, Sahar, Krizay, Daniel, Bera, Amal K, Yang, Mu, Peng, Yueqing, Makinson, Christopher D, Boland, Michael J, Frankel, Wayne N, Goldstein, David B, Dascal, Nathan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Research Foundation 18.05.2023
Frontiers Media S.A
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:mutations in , encoding the G subunit of G proteins, cause a neurodevelopmental disorder with global developmental delay and epilepsy, encephalopathy. Here, we show that mice carrying a pathogenic mutation, K78R, recapitulate aspects of the disorder, including developmental delay and generalized seizures. Cultured mutant cortical neurons also display aberrant bursting activity on multi-electrode arrays. Strikingly, the antiepileptic drug ethosuximide (ETX) restores normal neuronal network behavior and suppresses spike-and-wave discharges (SWD) . ETX is a known blocker of T-type voltage-gated Ca channels and G protein-coupled potassium (GIRK) channels. Accordingly, we present evidence that K78R results in a gain-of-function (GoF) effect by increasing the activation of GIRK channels in cultured neurons and a heterologous model ( oocytes)-an effect we show can be potently inhibited by ETX. This work implicates a GoF mechanism for GIRK channels in epilepsy, identifies a new mechanism of action for ETX in preventing seizures, and establishes this mouse model as a pre-clinical tool for translational research with predicative value for encephalopathy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present addresses: Sophie Colombo, Dynacure, Illkirch-Graffenstaden, France
Edited by: Haohua Qian, National Eye Institute (NIH), United States
Reviewed by: Fouad Lemtiri-Chlieh, University of Connecticut, United States; Stefano Taverna, San Raffaele Hospital (IRCCS), Italy
Sahar Gelfman, Regeneron Genetics Center, Tarrytown, New York, NY, United States
David B. Goldstein, Actio Biosciences, San Diego, CA, United States
ISSN:1662-5102
1662-5102
DOI:10.3389/fncel.2023.1175895